Nyxoah SA (NYXH) Fair Value 2026

NYXH · Surgical & Medical Instruments & Apparatus ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.0 /10

32 fundamental signals · 8 models active

Value Trap Risk

SAFE (18/100)

Quick Summary — As of 2026-07-15, Nyxoah SA (NYXH) trades at $1.61, approximately 436% above CirclFi’s Bayesian DCF fair value of $0.30. QOC: 5.0/10. Value Trap Risk: 18/100 (SAFE). 8/13 models active.

Key Facts

Ticker
NYXH
Price
$1.61
Quality Score
5.0/10
Value Trap Risk
18/100
Models Active
8/13
Last Updated
Strength: 8 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 5.0/10 signals weak fundamentals

Is Nyxoah SA (NYXH) Undervalued or Overvalued in 2026?

According to CirclFi’s 8-model valuation engine, Nyxoah SA (NYXH) appears overvalued as of : the median of 8 independent fair value estimates is $0.52, 67.7% below the current price of $1.61. Estimates range from $0.03 to $1.71. NYXH scores 5.0/10 on fundamental quality and 18/100 on value-trap risk.

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Nyxoah SA Stock in 2026? →

Valuation Matrix

8 Intrinsic Value Models vs. Current Price ($1.61)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
Low Conviction
 $0.30 -81.4%
Earnings Power Value
Low Conviction
 $0.03 -98.3%
CUCE Ensemble
Low Conviction
 $0.79 -51.0%
Dynamic NAV
High Conviction
 $0.42 -73.6%

Unlock the Full Matrix

Access 4 additional models including EROIC Spread, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 8 Models →

Cancel anytime · No contracts · Instant access

What Is Nyxoah SA (NYXH) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Nyxoah SA's intrinsic value is estimated at $0.70, suggesting the stock is overvalued at its current price of $1.61. With 6 out of 8 models flagging downside (-56.3% average return), the market may be pricing in unsustainable growth. The most optimistic model, PWERM, places fair value at $1.71 (+5.9%), while EPV — the most conservative — estimates $0.03 (-98.3%). This +104.2% gap reflects genuine analytical uncertainty about Nyxoah SA's intrinsic worth.

What Do the Models Say About NYXH?

8 of 13 models are currently active for NYXH. Of these, 2 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates NYXH's intrinsic value at $0.30, implying -81.4% downside from the current price. See which stocks rank higher →

How Does NYXH Rank in Surgical & Medical Instruments & Apparatus?

Among 109 Surgical & Medical Instruments & Apparatus stocks, NYXH ranks #89 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.

See all Most Undervalued Surgical & Medical Instruments & Apparatus Stocks →

Nyxoah SA operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is NYXH a Value Trap?

CirclFi's Value Trap algorithm assigns NYXH a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

8 of 13 models are active for Nyxoah SA. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Nyxoah SA's fundamental quality profile registers 5.0/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +104.2% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NYXH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NYXH's 8 active models, average confidence is 25%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Nyxoah SA Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Surgical & Medical Instruments & Apparatus Stocks Should You Also Analyze?

8 related Surgical & Medical Instruments & Apparatus stocks with 13-model coverage

DXCMDexCom, Inc.QOC 10.0IRMDiRadimed CorporationQOC 10.0PODDInsulet CorporationQOC 10.0RMDResMed Inc.QOC 10.0WSTWest Pharmaceutical Services, IQOC 9.9HAEHaemonetics CorporationQOC 9.8LMATLeMaitre Vascular, Inc.QOC 9.8GMEDGlobus Medical, Inc.QOC 9.2

Read investment analysis: DXCM · IRMD · PODD · RMD · WST

See all Surgical & Medical Instruments & Apparatus stocks ranked →

Frequently Asked Questions About Nyxoah SA

What is Nyxoah SA's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Nyxoah SA (NYXH) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $0.30. The Quality of Company score is 5.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NYXH overvalued or undervalued right now?

At $1.61, 2 of 8 active models suggest NYXH may be undervalued, while 6 indicate potential overvaluation. The median of all 8 fair value estimates is $0.52, 67.7% below the current price of $1.61 — a consensus view that NYXH is overvalued. The assessment depends on which methodology best fits Nyxoah SA's business model in Surgical & Medical Instruments & Apparatus.

What does a Quality of Company score of 5.0 mean for NYXH?

Nyxoah SA's QOC of 5.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on NYXH?

CirclFi analyzes NYXH with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 8 of 13 are active for this stock. Read the full methodology →

Is NYXH a value trap in 2026?

Nyxoah SA's Value Trap score is 18/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 8-model valuation engine, Nyxoah SA (NYXH) has a median fair value of $0.52 — 67.7% below the current price of $1.61 — as of 2026-07-15.” Source: circlfi.com/stock/NYXH/ · Methodology

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 8 mathematical frameworks give you clarity on NYXH.

Unlock All 8 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access